Spots in JUPITER

An FDA advisory committee will be addressing whether to expand the label indications for the cholesterol drug Crestor to include healthy individuals with NORMAL cholesterol levels. The data to support doing this come from the controversial JUPITER trial. The HCC interviewed Dr. Gordon Guyatt about the flaws of the trial.

Related, early stoppage of clinical trials can artificially inflate efficacy. JUPITER was halted early. Dr. Guyatt discusses this in detail.